Junfang Wu

SGLT2 inhibitor ameliorates hypertension by regulating the CYP4A/20-HETE pathway in the kidney

Sodium-Glucose Transport Protein 2 inhibitors (SGLT2i), initially developed as antidiabetic agents and now established as foundational therapies for heart failure, have also shown antihypertensive effects in clinical trials involving patients with diabetes and heart failure. Howe...